To the Editor,
Monogenic diabetes is relatively frequent in pediatric patients (2%-6%); among the monogenic forms, maturity onset diabetes of the young (MODY) is the most common [1] . MODY includes a number of heterogeneous disorders, whose pathogenesis does not involve autoimmunity; in fact, dysfunction of β cells is due to mutations of at least 14 different genes involved in glucose homeostasis [1] .
Clinical evolution and therapeutic approaches of the different MODY forms are variable; therefore, molecular diagnosis is extremely important to both clarify disease pathogenesis and choose the appropriate treatment [2] .
We report a case of a female patient, second child born to healthy non-consanguineous parents with an uneventful family history. This study was conducted according to the Declaration of Helsinki II and written informed consent was obtained from parents, for both the patient and themselves.
The patient came to our attention at 10 years of age because she developed diabetes mellitus.
The onset of diabetes was characterized by polyuria and polydipsia, hyperglycemia (13 mmol/L; RV: 3.9-5.5 mmol/L), elevated HbA 1c (51 mmol/mol; RV: <39 mmol/mol) and ketoacidosis. Autoimmune diabetes markers (GAD, IAA, IA2 and ZnT8) were negative; the patient did not show clinical signs of insulin resistance and alterations in kidney function or in nutritional status (creatinine: 35.4 μmol/L; RI: 35.4-61.9 μmol/L; albumin: 44 g/L; RI: 35-55 g/L). Considering the early onset of the disease, negative autoimmunity indexes and normal body mass index (BMI: 19.4, BMI z-score: 1.32), we decided to perform genetic tests for monogenic diabetes.
A more detailed evaluation of the patient's clinical history revealed a congenital interatrial defect, surgically treated at 2 years of age. In addition, at 8 months she developed seizures and is still treated with sodium valproate and levetiracetam. She also showed a slight psychomotor delay: she was unable to walk without support at 18 months, she pronounced her first words at 24 months and she attained bowel control at 30 months. Lack of social interaction was also observed; therefore, a WISC III test was performed which showed practical deficiencies and clinical manifestations of autism spectrum disorder. Physical examination revealed slanting of palpebral fissures, café-au-lait spots, tapering of the fingers (second and third toe bilateral syndactyly, fifth bilateral clinodactyly and sandal gap). The patient also showed minor skeletal malformations (scoliosis, hyperlordosis) and facial dysmorphisms (high forehead, thin upper lip, high palate). When she was 10 years old, she also developed Hashimoto's thyroiditis. Peripheral blood samples from both the patient and her healthy parents were collected and genomic DNA was extracted using automated MaGna pure instrument (Roche, Mannheim, Germany) and quantified using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA).
The acute onset of diabetes with ketoacidosis and high FPG value (13 mmol/L) suggested analysis of HNF1A and HNF4A genes for the diagnosis of monogenic diabetes; exons and flanking intron regions of these genes were amplified by PCR using previously reported primers [3] and sequenced in both directions using the Big Dye Terminator v.3.1 cycle sequencing kit (Life Technologies, Grand Island, NY, USA) on ABI PRISM sequencing apparatus 3730 (Applied Biosystems, Foster City, CA, USA). However, we did not detect any mutation in these genes after sequencing analysis; therefore, we sequenced the GCK gene. In fact, the HbA 1c value (51 mmol/mol) observed could not exclude a MODY2 diagnosis [2] . We did not detect pathogenic mutation in the GCK gene by sequencing, thus a gene dosage with multiplex ligation probe amplification (MLPA) methodology (MRC-Holland kit, Amsterdam, Holland) was performed following the manufacturer's instructions. A heterozygous deletion of the entire HNF1A gene was identified suggesting a MODY3 diagnosis. This alteration was absent in the parents suggesting the occurrence of a de novo mutation. To better clarify the complex phenotype of the patient and to define the extension of the deletion, a high resolution comparative genomic hybridization (CGH) array was performed using the Human Genome CGH Microarray Kit 4x180K (Agilent Technologies, Santa Clara, CA, USA), with an average space of 13 kb and allowing an average resolution of 25 kb [4] . Microarrays were scanned on an Agilent G2600D scanner and image files were quantified using Agilent's Feature Extraction software (V11.5.1.1); data were visualized with Agilent's Genomic Work Bench Standard Edition (V7.0.4.0). This analysis revealed a deletion of 1.04 Mb on chromosome 12, cytoband q24.31, from 120,838,585 to 121,882,127. The deleted region encompasses 20 OMIM genes: COX6A1, TRIAP1, GATC, SFRS9, DYNLL1, COQ5, RNF10, POP5, CABP1, MLEC, ACADS, SPPL3, HNF1A, OASL, P2RX7, P2RX4, CAMKK2, ANAPC5, RNF34 and partially KDM2B.
To date, three cases with similar deletions of 12q24.31 have been reported in the literature, all but one de novo [5] [6] [7] . The cases had clinical features similar to what we observed in our patient, including diabetes, developmental delay and typical dysmorphisms. Intellectual disability, seizures and behavioral problems were also observed in these patients (Table 1 ).
In all the four patients previously described, the observed deletions included the ACADS, SPPL3, HNF1A, OASL, P2RX7, P2RX4, CAMKK2, ANAPC5 and RNF34 genes (Figure 1) . The deletion of the aforementioned genes could explain some of the clinical signs present in all the patients. The patient described by Verhoeven et al. had a very similar gene deletion showing, on the other hand, a slightly different phenotype (Table 1 ). However, this patient also presented an interstitial gain of 150 kb in 5q22.3; therefore, differences with other patients could be due to this additional chromosomal alteration.
Among the deleted genes, HNF1A (OMIM 142410) codes for a transcriptional activator that regulates tissuespecific expression of multiple genes, especially in pancreatic islet cells and in the liver. Mutations in this gene determine a progressive β cell dysfunction with insulin deficiency and severe hyperglycemia associated with ketoacidosis similar to type 1 diabetes [11] .
HNF1A mutation carriers usually respond to sulfonylureas, oral hypoglycemic agents stimulating insulin secretion. In our patient, after confirming MODY3 diagnosis, insulin therapy was replaced with oral sulfonylureas with a significant improvement in the quality of life [2] .
Another deleted gene, ACADS (OMIM 606885), codes for a tetrameric mitochondrial flavoprotein; patients with homozygous mutations/deletions in ACADS present hypoglycemia, developmental delay, seizures and behavioral difficulties, while subjects with heterozygous alterations have only developmental delay, seizures and behavioral difficulties as observed in our patient [5] .
The P2RX7 (OMIM 602566) gene codes for a purinergic ion channel expressed on immune cells, microglia, astrocytes, oligodendrocytes and selected populations of neurons. P2RX7 gene variants have been associated in some studies with depression and bipolar disorders [5] .
The P2RX4 (OMIM 600846) gene codes for a purinergic receptor that functions as a ligand-gated ion channel with high calcium permeability. Genetic variants in P2RX4 and P2RX7 have been shown to affect susceptibility to multiple sclerosis [12] .
The CAMKK2 (OMIM 615002) gene encodes for one of the most highly expressed molecules in the central nervous system. The gene product is a key molecule in the Ca 2+ /calmodulin signaling cascade. Alterations in this gene were described in association with schizophrenia, epilepsy and bipolar disorders [13] .
SPPL3 (OMIM 608240), OASL (OMIM 603281), ANAPC5 (OMIM 606948) and RNF34 (OMIM 608299) genes, included in the deletion, are not actually associated to specific phenotypes; therefore, we could not clarify their contribution to the patient phenotype.
Additional cases of 12q24.31 deletion, involving a shorter common region not including the HNF1A gene, were reported [8] [9] [10] . As expected, the clinical manifestations in these patients were different: they did not include MODY3 and showed different facial dysmorphisms.
In conclusion, in this report, we describe a new case of 12q24.31 deletion and suggest that the presence of syndromic symptoms in non-autoimmune diabetic patients should lead to the evaluation of a common genetic etiology in order to understand the pathogenesis of any clinical sign and to offer genetic counseling and appropriate therapeutic indications.
